<DOC>
	<DOCNO>NCT01019941</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetic characteristic docetaxel two docetaxel product patient advance solid cancer .</brief_summary>
	<brief_title>Pharmacokinetic Study CKD-810 Taxotere Treat Patient With Advanced Solid Cancer</brief_title>
	<detailed_description>This Phase III study design evaluate pharmacokinetic characteristic docetaxel two docetaxel product patient advance solid cancer . This study also assess safety docetaxel advance solid cancer patient .</detailed_description>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient great 18 year age Advanced solid tumor locally advance metastatic breast cancer docetaxel alone therapy adequate locally advanced metastatic nonsmall cell lung cancer docetaxel alone therapy adequate locally advanced metastatic malignant tumor docetaxel alone therapy adequate Patient life expectancy least 3 month Patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Absolute neutrophil count ≥ 1,500/㎣ Platelet count ≥ 100,000/㎣ Hemoglobin ≥ 9.0g/dL Total Bilirubin ≤ 1.5 X ULN Alkaline Phosphatase ≤ 2.5 X ULN AST/ALT ≤ 2.0 X ULN Serum creatinine ≤ 1.5 X ULN Creatinine clearance ≥ 60mL/min ( Cockcroft equation ) Patients voluntarily sign write informed consent study entry If present , active bacterial infection parenteral antibiotic therapy . Patients may include infection resolve totally controlled state Brain metastasis neurologic symptom History unstable cardiac arrhythmia , congestive heart failure myocardial infarction within 6 month Known test positive HIV hepatitis B C Use inducer inhibitor CYP3A4 within 2 week prior first dose study medication . ( Patients may include patient need intake medication cimetidine keep dose continuously 1 cycle 2 cycle ) Peripheral neuropathy ≥ Grade 2 know resistant uncontrolled severe hypersensitivity docetaxel History hypersensitivity reaction Polysorbate 80 The female patient pregnancy , breast feeding childbearing potential . And patient laboratory result result positive serum pregnancy test , also Patients ( M/F ) reproductive potential implementing adequate contraceptive measurement . ( In case menopausal woman , keep menopause least 12 month . All sexually active male patient must agree use adequate method birth control throughout study ) Administration tumor therapy , include chemotherapy , radiotherapy , immunotherapy within 4 week begin study treatment . Patients may include radiotherapy conduct relieve symptom symptom recover grade 1 treated investigational drug within 4 week begin study treatment Must treat concurrent administration anticancer medicine Not able participate study , discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Docetaxel</keyword>
	<keyword>CKD-810</keyword>
	<keyword>Taxotere inj .</keyword>
	<keyword>Advanced Solid cancer</keyword>
	<keyword>Pharmacokinetic evaluation</keyword>
</DOC>